# Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP)

## Definitions
- **HAP**: Pneumonia occurring >= 48 hours after hospital admission, not incubating at time of admission
- **VAP**: Pneumonia developing > 48 hours after endotracheal intubation and mechanical ventilation
- **Ventilator-associated tracheobronchitis (VAT)**: Purulent secretions with positive cultures but no new infiltrate; may progress to VAP

## Risk Factors
- Mechanical ventilation > 48 hours (strongest risk factor for VAP)
- Prior IV antibiotic exposure within 90 days
- Hospitalization >= 5 days before pneumonia onset
- Acute respiratory distress syndrome (ARDS)
- Immunosuppression (steroids, chemotherapy, transplant)
- Structural lung disease (bronchiectasis, COPD)
- Known colonization with multidrug-resistant (MDR) organisms
- Aspiration risk (reduced consciousness, dysphagia, supine positioning)

## Common Pathogens
- **Gram-negative bacilli**: *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Escherichia coli*, *Acinetobacter baumannii*, *Enterobacter* spp.
- **Gram-positive**: MRSA (*Staphylococcus aureus*, methicillin-resistant)
- **Anaerobes**: Consider in aspiration events
- Late-onset (>= 5 days) and prior antibiotic exposure increase likelihood of MDR organisms

## Diagnostic Evaluation
- Obtain lower respiratory tract cultures (endotracheal aspirate or BAL) **before** initiating antibiotics
- Blood cultures x2 from separate sites
- Chest radiograph or CT showing new or progressive infiltrate
- Clinical criteria: new or worsening fever, leukocytosis or leukopenia, purulent secretions, declining oxygenation
- Procalcitonin can help guide duration but should not delay treatment

## Empiric Antibiotic Therapy

### Standard Risk (No MDR Risk Factors)
- Piperacillin-tazobactam 4.5 g IV q6h **or**
- Cefepime 2 g IV q8h **or**
- Meropenem 1 g IV q8h (reserve for beta-lactam allergy or local resistance patterns)

### High MDR Risk (Prior antibiotics, >= 5 days hospitalized, local MRSA prevalence > 10-20%)
Use **two** antipseudomonal agents from different classes **plus** MRSA coverage:
- Antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, or meropenem) **plus**
- Antipseudomonal fluoroquinolone (ciprofloxacin 400 mg IV q8h) or aminoglycoside (tobramycin or amikacin, dose per pharmacokinetics) **plus**
- MRSA coverage: vancomycin 15-20 mg/kg IV q8-12h (target trough AUC/MIC 400-600) **or** linezolid 600 mg IV q12h

### MRSA Coverage Indications
- Prior MRSA isolation or colonization
- ICU with MRSA prevalence > 10-20%
- Recent IV antibiotics within 90 days
- High severity of illness or septic shock
- Hemodialysis patients

## De-escalation Strategy
- **Review cultures at 48-72 hours** and narrow antibiotic spectrum based on susceptibility results
- Discontinue MRSA coverage if cultures are MRSA-negative
- Switch to single antipseudomonal agent if susceptibilities allow
- Transition IV to PO when patient is hemodynamically stable, tolerating oral intake, and clinically improving
- Stop aminoglycosides as soon as susceptibilities confirm beta-lactam activity

## Treatment Duration
- **HAP**: 7 days in most cases
- **VAP**: 7 days; may extend to 10-14 days for *Pseudomonas*, *Acinetobacter*, or immunosuppressed patients
- Serial procalcitonin trending can support earlier discontinuation
- Avoid prolonged courses (> 14 days) unless empyema, lung abscess, or inadequate source control

## Prevention Bundle (VAP Prevention)
- Elevate head of bed 30-45 degrees
- Daily sedation interruption and spontaneous breathing trials
- Oral care with chlorhexidine (per institutional protocol)
- DVT and stress ulcer prophylaxis
- Avoid unnecessary reintubation
- Minimize duration of mechanical ventilation
